Metabolomics analysis for biomarker discovery: advances and challenges.

Over the last decades there has been a change in biomedical research with the search for single genes, transcripts, proteins, or metabolites being substituted by the coverage of the entire genome, transcriptome, proteome, and metabolome with the "omics" approaches. The emergence of metabolomics, defined as the comprehensive analysis of all metabolites in a system, is still recent compared to other "omics" fields, but its particular features and the improvement of both analytical techniques and pattern recognition methods has contributed greatly to its increasingly use. The feasibility of metabolomics for biomarker discovery is supported by the assumption that metabolites are important players in biological systems and that diseases cause disruption of biochemical pathways, which are not new concepts. In fact, metabolomics, meaning the parallel assessment of multiple metabolites, has been shown to have benefits in various clinical areas. Compared to classical diagnostic approaches and conventional clinical biomarkers, metabolomics offers potential advantages in sensitivity and specificity. Despite its potential, metabolomics still retains several intrinsic limitations which have a great impact on its widespread implementation - these limitations in biological and experimental measurements. This review will provide an insight to the characteristics, strengths, limitations, and recent advances in metabolomics, always keeping in mind its potential application in clinical/ health areas as a biomarker discovery tool.

[1]  J. Chen,et al.  Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography‐mass spectrometry methods: Differential metabolite discovery specific to ovarian cancer , 2012, Electrophoresis.

[2]  M. Tomita,et al.  Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy , 2012, Analytical and Bioanalytical Chemistry.

[3]  Mahlet G Tadesse,et al.  Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. , 2012, Analytica chimica acta.

[4]  R. Weiss,et al.  Urinary acylcarnitines are altered in human kidney cancer , 2012, International journal of cancer.

[5]  A. Zhang,et al.  Serum metabolomics as a novel diagnostic approach for disease: a systematic review , 2012, Analytical and Bioanalytical Chemistry.

[6]  Tao Zhang,et al.  Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[7]  Ming-zhu Yin,et al.  Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform , 2012, Acta oncologica.

[8]  G. Siuzdak,et al.  Innovation: Metabolomics: the apogee of the omics trilogy , 2012, Nature Reviews Molecular Cell Biology.

[9]  Hui Sun,et al.  Recent and potential developments of biofluid analyses in metabolomics. , 2012, Journal of proteomics.

[10]  Caroline H. Johnson,et al.  Xenobiotic metabolomics: major impact on the metabolome. , 2012, Annual review of pharmacology and toxicology.

[11]  E. Fukusaki,et al.  A metabolomic approach to lung cancer. , 2011, Lung cancer.

[12]  R. Weiss,et al.  Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. , 2011, Omics : a journal of integrative biology.

[13]  Ping Liu,et al.  Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma* , 2011, Molecular & Cellular Proteomics.

[14]  Xiaohua Wu,et al.  Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. , 2011, Journal of proteome research.

[15]  Oliver F Bathe,et al.  Metabolomics and surgical oncology: Potential role for small molecule biomarkers , 2011, Journal of surgical oncology.

[16]  G. Siuzdak,et al.  Expanding coverage of the metabolome for global metabolite profiling. , 2011, Analytical chemistry.

[17]  A. Astrup,et al.  Standardization of factors that influence human urine metabolomics , 2011, Metabolomics.

[18]  Kurt Miller,et al.  Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. , 2011, The Journal of urology.

[19]  P. Prenzler,et al.  Recent and potential developments in the analysis of urine: a review. , 2011, Analytica chimica acta.

[20]  Vitor Sousa,et al.  Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. , 2011, Journal of proteome research.

[21]  Oliver F Bathe,et al.  Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[22]  Olaf Tietje,et al.  Differential Volatile Signatures from Skin, Naevi and Melanoma: A Novel Approach to Detect a Pathological Process , 2010, PloS one.

[23]  Subramaniam Pennathur,et al.  Analytical approaches to metabolomics and applications to systems biology. , 2010, Seminars in nephrology.

[24]  Ning Zhang,et al.  Plasma metabolomics reveals biomarkers of the atherosclerosis. , 2010, Journal of separation science.

[25]  Yuqin Wang,et al.  Targeted metabolomics for biomarker discovery. , 2010, Angewandte Chemie.

[26]  M. Hirai,et al.  MassBank: a public repository for sharing mass spectral data for life sciences. , 2010, Journal of mass spectrometry : JMS.

[27]  G. Kristiansen,et al.  Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. , 2010, European urology.

[28]  J. Schalken Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. , 2010, European urology.

[29]  E. Go,et al.  Database Resources in Metabolomics: An Overview , 2010, Journal of Neuroimmune Pharmacology.

[30]  R. Lewensohn,et al.  Metabolomics: Moving to the Clinic , 2010, Journal of Neuroimmune Pharmacology.

[31]  H. Oka,et al.  Urinary Volatile Compounds as Biomarkers for Lung Cancer: A Proof of Principle Study Using Odor Signatures in Mouse Models of Lung Cancer , 2010, PloS one.

[32]  Paul B Watkins,et al.  Effects of a prolonged standardized diet on normalizing the human metabolome. , 2009, The American journal of clinical nutrition.

[33]  Younghoon Kim,et al.  Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification , 2009, Bioinform..

[34]  David S. Wishart,et al.  SMPDB: The Small Molecule Pathway Database , 2009, Nucleic Acids Res..

[35]  Augustin Scalbert,et al.  The complex links between dietary phytochemicals and human health deciphered by metabolomics. , 2009, Molecular nutrition & food research.

[36]  J. Jansson,et al.  Metabolomics Reveals Metabolic Biomarkers of Crohn's Disease , 2009, PloS one.

[37]  Oliver Fiehn,et al.  Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research , 2009, Metabolomics.

[38]  Arjen Lommen,et al.  MetAlign: interface-driven, versatile metabolomics tool for hyphenated full-scan mass spectrometry data preprocessing. , 2009, Analytical chemistry.

[39]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[40]  Timothy D Veenstra,et al.  How close is the bench to the bedside? Metabolic profiling in cancer research , 2009, Genome Medicine.

[41]  S. Eckhardt,et al.  Clinical Applications of Metabolomics in Oncology: A Review , 2009, Clinical Cancer Research.

[42]  Christian Gieger,et al.  Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum , 2008, PLoS genetics.

[43]  David S. Wishart,et al.  HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..

[44]  J. Lindon,et al.  Systems biology: Metabonomics , 2008, Nature.

[45]  Marta Cascante,et al.  Metabolomics and fluxomics approaches. , 2008, Essays in biochemistry.

[46]  John C. Lindon,et al.  Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery , 2008 .

[47]  W. Matson,et al.  Metabolomic profiling to develop blood biomarkers for Parkinson's disease. , 2008, Brain : a journal of neurology.

[48]  R. Weinshilboum,et al.  Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.

[49]  B. Seliger,et al.  Candidate biomarkers in renal cell carcinoma , 2007, Proteomics.

[50]  Erik J. Saude,et al.  Variation of metabolites in normal human urine , 2007, Metabolomics.

[51]  Russ Greiner,et al.  Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. , 2007, Analytical chemistry.

[52]  Nigel W. Hardy,et al.  The Metabolomics Standards Initiative , 2007, Nature Biotechnology.

[53]  Marco Oldiges,et al.  Metabolomics: current state and evolving methodologies and tools , 2007, Applied Microbiology and Biotechnology.

[54]  David I. Ellis,et al.  Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate , 2007, Metabolomics.

[55]  Rima Kaddurah-Daouk,et al.  A preliminary metabolomic analysis of older adults with and without depression , 2007, International journal of geriatric psychiatry.

[56]  Oliver Fiehn,et al.  A comprehensive urinary metabolomic approach for identifying kidney cancerr. , 2007, Analytical biochemistry.

[57]  G. Siuzdak,et al.  From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. , 2007, Journal of proteome research.

[58]  M. Moyer,et al.  Determination of volatile products of human colon cell line metabolism by GC/MS analysis , 2007, Metabolomics.

[59]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[60]  Yi-Zeng Liang,et al.  Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS‐LDA , 2006, FEBS letters.

[61]  Masaru Tomita,et al.  MathDAMP: a package for differential analysis of metabolite profiles , 2006, BMC Bioinformatics.

[62]  K. Robards,et al.  Metabolomics: The greatest omics of them all? , 2006, Analytical chemistry.

[63]  M. Walsh,et al.  Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. , 2006, The American journal of clinical nutrition.

[64]  Royston Goodacre,et al.  Metabolomics: Current technologies and future trends , 2006, Proteomics.

[65]  Nigel W. Hardy,et al.  Establishing reporting standards for metabolomic and metabonomic studies: a call for participation. , 2006, Omics : a journal of integrative biology.

[66]  R. Kaddurah-Daouk Metabolic Profiling of Patients with Schizophrenia , 2006, PLoS medicine.

[67]  Elaine Holmes,et al.  Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia , 2006, PLoS medicine.

[68]  John C. Lindon,et al.  Metabolomics Standards Workshop and the development of international standards for reporting metabolomics experimental results , 2006, Briefings Bioinform..

[69]  Matej Oresic,et al.  MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data , 2006, Bioinform..

[70]  R. Abagyan,et al.  XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. , 2006, Analytical chemistry.

[71]  Pei-yin Lin,et al.  Kidney cancer: identification of novel targets for therapy. , 2006, Kidney international.

[72]  Frederick P Roth,et al.  Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia , 2005, Circulation.

[73]  R. Abagyan,et al.  METLIN: A Metabolite Mass Spectral Database , 2005, Therapeutic drug monitoring.

[74]  Simone Rochfort,et al.  Metabolomics reviewed: a new "omics" platform technology for systems biology and implications for natural products research. , 2005, Journal of natural products.

[75]  Jianren Gu,et al.  Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. , 2005, Analytical chemistry.

[76]  W. Dunn,et al.  Measuring the metabolome: current analytical technologies. , 2005, The Analyst.

[77]  Yves Gibon,et al.  GMD@CSB.DB: the Golm Metabolome Database , 2005, Bioinform..

[78]  David I. Ellis,et al.  Metabolomics: Current analytical platforms and methodologies , 2005 .

[79]  Bruce D. Hammock,et al.  Metabolomics: building on a century of biochemistry to guide human health , 2005, Metabolomics.

[80]  Alan Hutson,et al.  Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics , 2005, International journal of cancer.

[81]  Qing Yang,et al.  Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[82]  J. van der Greef,et al.  The role of analytical sciences in medical systems biology. , 2004, Current opinion in chemical biology.

[83]  J. Griffin Metabolic profiles to define the genome: can we hear the phenotypes? , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[84]  D. Kell,et al.  Metabolomics by numbers: acquiring and understanding global metabolite data. , 2004, Trends in biotechnology.

[85]  W. Weckwerth Metabolomics in systems biology. , 2003, Annual review of plant biology.

[86]  J. Nicholson,et al.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.

[87]  R. Takors,et al.  Metabolomics: quantification of intracellular metabolite dynamics. , 2002, Biomolecular engineering.

[88]  Ravi Iyengar,et al.  Systems biology of kidney diseases. , 2012, Kidney international.

[89]  Kyoungmi Kim,et al.  Metabolomics in the study of kidney diseases , 2012, Nature Reviews Nephrology.

[90]  C. Edelstein Biomarkers in kidney disease , 2011 .

[91]  C. Milikowski,et al.  A case report - Volatile metabolomic signature of malignant melanoma using matching skin as a control. , 2011, Journal of cancer science & therapy.

[92]  R. Goodacre,et al.  The role of metabolites and metabolomics in clinically applicable biomarkers of disease , 2010, Archives of Toxicology.

[93]  Christina D. Smolke,et al.  The metabolic pathway engineering handbook , 2010 .

[94]  Ute Roessner,et al.  What is metabolomics all about? Biotechniques , 2009 .

[95]  Feng Wang Biomarker Methods in Drug Discovery and Development , 2008, Methods in Pharmacology and Toxicology™.

[96]  Huanwen Chen,et al.  Monitoring diet effects via biofluids and their implications for metabolomics studies. , 2007, Analytical chemistry.

[97]  B. Hammock,et al.  Mass spectrometry-based metabolomics. , 2007, Mass spectrometry reviews.

[98]  O. Fiehn Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.

[99]  J. Lindon,et al.  So what's the deal with metabonomics? , 2003, Analytical chemistry.

[100]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[101]  Zhi Chen,et al.  Revised Papers , 2022 .

[102]  B. Hammock,et al.  Perspectives Editorial Guest Editorial , 2022 .

[103]  Pierre Baldi,et al.  ChemDB: a public database of small molecules and related chemoinformatics resources , 2005, Bioinform..